Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Senhwa Biosciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Senhwa Biosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Senhwa Biosciences is high growth as no earnings estimate data is available.
Senhwa Biosciences's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Senhwa Biosciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Senhwa Biosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Senhwa Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Senhwa Biosciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Senhwa Biosciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Senhwa Biosciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Tai-Sen Soong, Ph.D. is a Co-Founder of Medtech Tronics, Inc. Dr. Soong serves as the President and Vice Chairman at CDIB BioScience Venture Management. Dr. Soong serves as Chief Executive Officer and President at Senhwa Biosciences, Inc. He also served as Head of Life Science Investment Unit in Overseas Business Department at CDIB since 1999. Prior to joining CDIB, he had also served as the Managing Director at Imagen Venture Holdings. Dr. Soong served as the Director of Taiwan's Development Center for Biotechnology from 1986 to 1995, he established a research and development base for commercial application of biotechnology and promoted Taiwan's biotech industry through product development and technology transfer. Dr. Soong was a Research Specialist at Monsanto Corp. He serves as a Founding Member and Board of Directors of Panlabs Biologics, HenKan Pharmaceuticals, and Medtech Tronics, Inc. He has been Director of CDIB BioScience Venture Management since December 2001. He was a Professor at National University of Singapore. During his service in Singapore, Dr. Soong successfully launched Singapore China Biotechnology Program to introduce scientists from mainland China to assist biotechnology development in Singapore. He received a Ph.D. in Biology from University of Illinois Urbana-Champaign.
Insufficient data for Tai-Sen to compare compensation growth.
Insufficient data for Tai-Sen to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
CEO & President
CFO and Head of Finance & Administration
Vice President and General Counsel
Board of Directors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Senhwa Biosciences, Inc., a clinical-stage drug development company, identifies and develops therapies for the treatment of cancer. The company is developing CX-4945 that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-5461 AU, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; and CX-5461 CA, which is in phase I clinical trials in patients with solid tumors and breast cancer. It is also developing CX-4945-07, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and PBTC-053, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. The company was founded in 2012 and is based in New Taipei City, Taiwan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.